AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03259256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation of intrahepatic islet
Description: Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
Study NCT01580826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pasteurization of mother's own milk
Description: mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
Study NCT03803163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon Treprostinil
Study NCT02588586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: 3BNC117 infusions
Study NCT02588586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral Treatment Interruption
Description: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
Study NCT02705378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
Study NCT02705378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxegol
Description: Intervention would be given by OG or NG tube
Study NCT03343366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
Study NCT03343366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling Root Planing
Description: SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
Study NCT03343366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling Root Planing
Description: SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
Study NCT03343366 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
Study NCT03343366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
Study NCT03343366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instructions
Description: OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
Study NCT01481883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene Hydrochloride
Description: 120mg daily - 1 capsule daily for 12 week trial
Study NCT01481883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 week trial
Study NCT00593424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat/High Carbohydrate
Description: Low Fat/High Carbohydrate for 6 week period
Study NCT00593424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Monounsaturated Fat/Low Carbohydrate
Description: High Monounsaturated Fat/Low Carbohydrate for 6 week period
Study NCT03321201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cauterization
Description: To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
Study NCT03321201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin glue
Description: Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
Study NCT01923324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician telephone consultation
Description: Pain physician support for family physician treating patient
Study NCT01923324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual family physician care
Description: Usual family physician care without telephone consultation with pain physician
Study NCT04521478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study NCT04521478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04521478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine
Study NCT04392219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIDD-2801
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Study NCT04392219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Study NCT02876861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Description: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
Study NCT02876861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical nephroureterectomy
Description: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
Study NCT02876861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal ureterectomy
Description: Distal ureterectomy.
Study NCT02876861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal ureterectomy
Description: Distal ureterectomy.
Study NCT02876861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
Study NCT02962232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Description: treatment group
Study NCT02962232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA catheter
Description: control group
Study NCT01463943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT01463943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT01703169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
Study NCT00195195 — intervention group
Intervention type: DRUG
Intervention: Sirolimus
Description: Transplantation patients treated with sirolimus who consent to participate in the study (register)
Study NCT01207011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin hydrocloride
Description: AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
Study NCT01207011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
Study NCT02360423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRE8 sirolimus-eluting stent
Description: The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
Study NCT02360423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESOLUTE zotarolimus-eluting stent
Description: The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
Study NCT00315614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Transplantation and Bone Marrow
Description: Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Anti-mycobacterial oral drug
Study NCT02372383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancreatic enzyme replacement therapy
Study NCT03176641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Autologous platelet-rich plasma gel applied during meniscus repair surgery
Study NCT03176641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Meniscus repair surgery only
Study NCT02446548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
Study NCT02446548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
Study NCT02446548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
Study NCT04145206 — intervention group
Intervention type: BEHAVIORAL
Intervention: Flamenco dance
Description: evaluation of ankle injuries in the flamenco dancers
Study NCT01008774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Cooling Machine
Description: Scalp cooling procedures
Study NCT01008774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Caps
Description: Scalp cooling procedures
Study NCT03800680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Management Package (DMP)
Description: M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed.
Study NCT03800680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-POWER Rewards
Description: A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
Study NCT00484926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: stopping clopidogrel at 1 year after DES
Study NCT00484926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study NCT03908554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WORKPLACE HEALTH PROMOTION PROGRAM
Description: WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
Study NCT02761096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session.
Study NCT02761096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
Study NCT02761096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
Study NCT06546215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
Study NCT06546215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
Study NCT01443234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxIGen
Description: Internet-based intervention with 12 sessions over 4 weeks
Study NCT01443234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OxIGen: control version
Description: A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
Study NCT00568737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: Drotrecogin Alfa (activated)
Study NCT00568737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT03365518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
Study NCT03365518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy
Description: The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
Study NCT00437060 — intervention group
Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT00437060 — intervention group
Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging
Description: Correlative studies
Study NCT00437060 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00437060 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00437060 — intervention group
Intervention type: PROCEDURE
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Lowest Dose
Description: 1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Low Dose
Description: 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Middle Dose
Description: 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - High Middle Dose
Description: 1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - High Dose
Description: 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-4217329 - Highest Dose
Description: 1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Vehicle
Description: 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Vehicle
Description: 1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Low Dose
Description: Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Middle Dose
Description: Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - High Dose
Description: Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Description: 1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Low Dose
Description: Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
Study NCT00572455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329 - Middle Dose
Description: Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.